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Abstract Intracellular production of nitric oxide (NO) is 
thought to mediate the pancreatic B-cell-directed cytotoxicity 
of cytokines in insulin-dependent diabetes mellitus, and recent 
evidence has indicated that this may involve induction of 
apoptosis. A primary effect of NO is to activate soluble guanylyl 
cyclase leading to increased cGMP levels and this effect has been 
demonstrated in pancreatic B-cells, although no intracellular 
function has been defined for islet cGMP. Here we demonstrate 
that the NO donor, GSNO, induces apoptosis in the pancreatic 
B-celliine HIT-TI5 in a dose- and time-dependent manner. This 
response was significantly attenuated by micromolar concentra-
tions of a specific inhibitor of soluble guanylyl cyclase, ODQ, 
and both 8-bromo cGMP (100 ~) and dibutyryl cGMP 
(300 ~) were able to fully relieve this inhibition. In addition, 
incubation of HIT -T15 cells with each cGMP analogue directly 
promoted cell death in the absence of ODQ. KT5823, a potent 
and highly selective inhibitor of cGMP-dependent protein kinase 
(PKG), abolished the induction of cell death in fiT cells in 
response to either GSNO or cGMP analogues. This effect was 
dose-dependent over the concentration range of 10--250 nM. 
Overall, these data provide evidence that the activation of 
apoptosis in HIT-TI5 cells by NO donors is secondary to a rise 
in cGMP and suggest that the pathway controlling cell death 
involves activation of PKG. 
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1. Introduction 
Insulin-dependent diabetes mellitus (IDDM) is an autoim-
mune disease characterised by macrophage and T-cell infiltra-
tion of the endocrine pancreas, resulting in insulitis and spe-
cific destruction of islet B-cells. The cytotoxic attack is 
mediated by cytokines (especially interleukin 1-13) secreted 
by the infiltrating immune cells. There is a considerable 
body of evidence suggesting that cytokine-induced death of 
pancreatic B-cells derives from the induction of nitric oxide 
synthase (iN OS) leading to generation of NO within the cells 
(reviewed in [1]; see also [2-5]). NO then interacts with a 
variety of intracellular targets which contain either haem 
groups or iron-sulphur centres, including respiratory carries 
and metabolic enzymes [6]. The functional consequences of 
*Corresponding author. Fax: (44) 1782-630007. 
E-mail: n.g.morgan@cc.keele.ac.uk 
Abbreviations: GC, guanylyl cyclase; GSNO, S-nitrosoglutathione; 
iNOS, inducible nitric oxide synthase; NO. nitric oxide; ODQ, IH-
[I ,2,4]oxadiazolo[4,3-a]quinoxalin-I-one; PKG, cGMP-dependent 
protein kinase 
these interactions may then mediate some of the cytotoxic 
effects of the molecule. 
In a number of cell types, including macrophages, thymo-
cytes and chondrocytes [7-9], recent evidence has suggested 
that generation of NO can lead to induction of cell death by 
activation of apoptosis. Moreover, it is now evident that cy-
tokines and a variety of chemical NO donors also induce 
apoptosis in freshly isolated rat islets and in clonal pancreatic 
B-cell lines [10-1W. The mechanisms by which this occurs 
remain undefined, although NO is known to cause direct dam-
age to DNA by deamination of purines and pyrimidines [14], 
in addition to exerting inhibitory effects on metabolic en-
zymes. A further well-characterised effect of NO is the activa-
tion of soluble guanylyl cyclase (GC), leading to increased 
levels of intracellular cGMP [15-17] and subsequent activa-
tion of a cGMP-dependent protein kinase, PKG. Pancreatic 
islets express GC [18] but the role of cGMP in islet cell signal-
ling remains enigmatic [19,20]. Indeed, the cumulative evi-
dence indicates that modulation of cGMP levels is not in-
volved in the acute regulation of insulin synthesis or 
secretion [21]. 
In the present work, we have investigated the possibility 
that a hitherto unrecognised function of the GC-PKG system 
in pancreatic B-cells may be to regulate the entry of these cells 
into the apoptotic pathway. The glucose-responsive B-cell 
line, HIT-Tl5, was induced to enter apoptosis by incubation 
with the NO donor, GSNO and the results revealed that 
GSNO-induced apoptosis was significantly attenuated by a 
specific inhibitor of GC, ODQ. Cell permeant cGMP analo-
gues were able to fully restore GSNO-induced apoptosis in the 
presence of ODQ. Furthermore, analogues of cGMP were 
also able to induce cell death directly in HIT-Tl5 cells, a 
response which was abolished by the selective PKG inhibitor 
KT5823. This agent also dose-dependently inhibited the in-
duction of apoptosis by GSNO. This suggests that, among 
the numerous reported effects of NO, activation of the 
cGMP pathway is of paramount importance in the induction 
of apoptosis in pancreatic B-cells. 
2. Experimental procedures 
HIT -TI5 cells were seeded at I X 105 cells/well in 24-well plates in 
RPMI-1640 medium supplemented with I-glutamine (300 Ilglml), so-
dium penicillin G (100 IV/ml), streptomycin sulphate (100 Ilglml) and 
foetal calf serum (10%) and incubated in a air/C02 atmosphere 
(95:5%), with 100% humidity, for 48 h. Cells were then treated with 
test reagents for 1-24 h, after which time detached cells were har-
vested by centrifugation of the medium (500xg/2 min). In experi-
ments involving co-incubation with apoptosis-inducing agents 
(GSNO or cGMP analogues) and the enzyme inhibitors ODQ or 
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KTS823, cells were pre-incubated with the inhibitors for 30 and 60 
min, respectively. Dead cells counts were carried out using vital dye 
(Trypan blue) exclusion and heamocytometry. Apoptosis was con-
firmed by electron microscopy, DNA gel electrophoresis and fluoro-
microscopic examination of acridine orange-stained cells, using the 
methods described by Morgan et al. [22]. Statistical analysis was car-
ried out using I-way analysis of variance and Tukey's test of least 
significant difference. 
3. Results and discussion 
In agreement with previous work using other NO donors 
[10,11], GSNO was found to induce apoptosis in the B-cell 
line, HIT-TIS. The concentrations of GSNO required to in-
duce HIT cell death were low compared to those employed in 
other cell types, with as little as 100 11M GSNO promoting a 
significant increase in cell death compared to untreated con-
trols (Fig. 1). Many chemical NO donors are thought to have 
a relatively short half-life after hydration, but GSNO differs in 
that it induces a sustained, low-level production of NO for 
several hours in tissue culture medium (R.D. Hurst, personal 
communication). The significance of this for the time course 
of induction of apoptosis is unclear but increased cell death 
only became evident following exposure of HIT cells to 
GSNO for 3-5 h (Fig. 2). Apoptosis is known to require de 
novo protein synthesis in many cell types and the time-course 
observed for the onset of death in these experiments is con-
sistent with this mechanism in pancreatic B-cells. Examination 
of the cells by acridine orange staining and fluoromicroscopy 
revealed that at least 7S-80% of the detached cells from each 
condition showed evidence of chromatin condensation and 
margination, indicating that the cells had died by apoptosis 
(not shown). Taking this with the S-20-fold increase in de-
tached, dead cell numbers resulting from GSNO treatment, 
quantified by vital staining, it can be seen that GSNO con-
sistently induced a significant increase in the number of apop-
totic cells, compared to untreated controls. Cells that re-
mained attached to the substrate were found to be viable, 
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Fig. 1. Dose-response relationship for the induction of cell death by 
GSNO. HIT-TIS cells were cultured for an initial period of 48 h 
and then exposed to increasing concentrations of GSNO (0-200 
flM). Detached cells were harvested and the numbers of non-viable 
cells determined by vital staining. Each point represents the mean 
dead cell count ± SEM (n = 8). * P < 0.001 compared to control. 
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Fig. 2. Time course of cell death induced by GSNO in HIT-TIS 
cells. HIT-TIS cells were cultured for 48 h and then exposed to 
200 flM GSNO for a further 1-24 h. Detached cells were harvested 
and the numbers of non-viable cells determined by vital staining. 
Each point represents the mean of 6 replicates ± SEM. * P < 0.001 
compared to control. 
apoptosis in B-cells. This observation is consistent with the 
recognised progression of apoptosis, where retraction of ex-
tracellular contacts is an early event [23]. The mechanism of 
cell death was confirmed as apoptosis by two further methods. 
Electron microscopy revealed that cells exposed to GSNO 
exhibited morphological features of apoptosis (Fig. 3A) and 
DNA was extracted from GSNO-treated cells prior to exam-
ination by agarose-gel electrophoresis. The DNA exhibited an 
oligonucleosomal laddering pattern that is typical of cells dy-
ing by apoptosis (Fig. 3B). 
Since NO donors are well known to promote a rise in 
cGMP levels by virtue of their ability to cause activation of 
soluble GC, HIT cells were treated with cell permeant analo-
gues of cGMP (8-bromo-cGMP; dibutyryl cGMP) and their 
responses monitored. Both analogues caused a marked in-
crease in HIT cell death during 24 h exposure (100 11M 
8b-cGMP, 296 ± 20%; 300 11M dbcGMP, 228 ± IS% vs. con-
trol; P<O.OOI; see also Fig. 6) suggesting that elevation of 
cGMP may be a primary component of the signalling path-
way leading to activation of apoptosis in pancreatic B-cells. In 
order to examine this possibility further, cells were exposed to 
GSNO in the presence of a specific inhibitor of soluble GC, 
ODQ [24]. This agent failed to alter the extent of cell death in 
control cells but significantly inhibited the capacity of 200 11M 
GSNO to cause HIT cell death. Over several experiments, 
10 11M ODQ exerted a consistent 60-6S% inhibition of the 
response to GSNO. Addition of either 8-bromo-cGMP or 
dibutyryl cGMP to cells incubated with GSNO totally pre-
vented the inhibitory effect of ODQ, confirming the involve-
ment of cGMP in the death response (Fig. 4). 
The actions of cGMP can be mediated by several intracel-
lular target proteins including certain ion channels, phospho-
diesterase enzymes and cGMP-dependent protein kinases. In 
order to examine which of these is involved in the induction 
of apoptosis by cGMP in pancreatic B-cells, HIT cells were 
treated with a highly selective inhibitor of PKG, KT5823 
[2S-27]. This agent did not influence the viability of control 






Fig. 3. Evidence for induction of apoptosis in GSNO-treated HIT-Tl5 cells. A: Following 24 h exposure to GSNO, detached HIT-Tl5 cells 
were harvested and fixed with gluteraldehyde prior to processing for electronmicroscopy. A typical example is shown in which marked conden-
sation and margination of chromatin is evident. These features are indicative of death by apoptosis. B: HIT-TI5 cells were cultured for 24 h in 
the presence (lane 2) or absence (lane 1) of 200 11M GSNO. Approximately 106 detached cells were harvested and lysed prior to DNA extrac-
tion. The DNA was electrophoresed on a 2% agarose gel, stained with ethidium bromide and visualised under UV light. 
cells but it potently inhibited the induction of cell death by 






















Fig. 4. Inhibition of GSNO-induced cell death by ODQ and relief 
by cGMP analogues. HIT-Tl5 cells were incubated for 24 h in the 
absence (open bar) or presence (shaded bars) of 200 11M GSNO. 10 
11M ODQ was introduced (bars 3-5) and further supplemented with 
either 100 11M 8-bromo-cGMP (lane 4) or 300 11M dibutyryl cGMP 
(lane 5). Detached cells were harvested and the number of dead cells 
quantified by vital staining. Each point represents the mean of 6 
replicates ± SEM. * P < 0.001 compared to control. ** P < 0.001 
relative to GSNO alone. ***P< 0.001 relative to GSNO+ODQ. 
nM of the inhibitor and complete abolition of the response to 
GSNO was seen with 250 nM KT5823 (Fig. 5). Strikingly, 
KT5823 also totally prevented the induction of HIT cell death 
by cGMP analogues (Fig. 6) indicating that both GSNO and 
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Fig. 5. Inhibition of GSNO-induced cell death by the protein kinase 
G inhibitor, KT5823. HIT-Tl5 cells were cultured for 48 h, then 
pre-incubated for 1 h with varying concentrations of KT5823 
(0-500 nM). Cells were then exposed to 200 11M GSNO for a 
further 5 h. Detached cells were harvested and the number of non-
viable cells quantified by vital staining. All concentrations of 
KT5823 between 50-250 nM significantly inhibted GSNO-induced 
cell death (P<O.OOI compared to GSNO alone; n=4-S). 
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Fig. 6. Effect of KT5823 on HIT-Tl5 cell death induced by cGMP 
analogues. HIT-Tl5 cells were cultured for an initial period of 48 h, 
then incubated for a further 24 h under control conditions (open 
bar), in the presence of 500 nM KT5823 alone (bar 2) or with 100 
~M 8-bromo-cGMP (8bcG) or 300 ~M dibutyryl cGMP (dbcG) in 
the absence or presence of 500 nM KT5823 (KT) as shown. De-
tached cells were harvested and the dead cell count determined by 
vital staining (n = 6). * P < 0.001 compared to untreated cells. 
** P < 0.001 compared to each cGMP analogue alone. 
the cGMP analogues require activation of PKG in order to 
induce HIT cell death. 
Overall, the results of the present study provide evidence 
that activation of apoptosis in pancreatic B-cells can occur in 
response to agents which promote a rise in cGMP levels. The 
data are consistent with the novel possibility that generation 
of cGMP and subsequent activation of PKG represent impor-
tant components in a signalling pathway controlling apoptosis 
in B-cells. The downstream effectors by which this pathway 
induces cell death remain to be identified but it may be sig-
nificant that PKG has recently been identified as an important 
regulator of the transcription of certain early response genes 
such as c-fos which are often expressed in cells entering apop-
tosis and are involved in control of cell growth and differen-
tiation [26,28]. In this context, it is noteworthy that treatment 
of islet cells with cytokines (e.g. interleukin l-~) leads to a rise 
in cGMP [29] and an increase in c-fos expression [30,31]. The 
temporal relationship between these events requires further 
study but the possibility should not be excluded that cGMP 
may be central to the cytotoxic actions of cytokines in islet 
cells. In a still wider context, the recent findings that cGMP-
dependent pathways are involved in regulation of cell senes-
cence and growth arrest in a number of cell types [26,32] 
suggest that the activation state of PKG may be an important 
regulatory factor which determines the ultimate fate of a cell 
according to the prevailing cGMP level. Furthermore, if, as 
suggested by the present results, the cGMP-PKG pathway 
proves to be crucially involved in the regulation of islet cell 
death, then manipUlation of this pathway may offer a unique 
therapeutic route to intervene in the early loss of B-cells as-
sociated with progression towards insulin-dependent diabetes 
mellitus. 
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